RxDoctor Payments Data

George Katsantonis, MD

Otolaryngology · Sikeston, MONPI 1184610693

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (57.2%), food and beverage and education — rather than concentrated in one kind of arrangement. 12 manufacturers reported payments, led by Aerin Medical Inc. at 45.4% of the total. 2025 is the largest year on record at $1,499, more than ten times the $86 reported in 2019.

$3,367in general payments, 2019–2025

Across 55 payments — averaging $61.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Aerin Medical Inc.$2K
  • Acclarent, Inc$1K
  • Regeneron Healthcare Solutions, Inc.$248
  • Sanofi$179
  • Stryker$94
  • GSK$44
  • plus $89 from 6 others

What the payments were for

  • Travel & lodging$1,92757%
  • Food & beverage$1,33840%
  • Education$983%
  • Gifts$40%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,367 in reported general payments places this provider in the 80th percentile of 210 otolaryngology providers in Missouri.

See all otolaryngology providers in Missouri

Medicare billing

Part B allowed, 2024
$49,365
Medicare patients
352
Services billed
715

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XhanceFluticasone Propionate15$9,782
Ciprofloxacin-DexamethasoneCiprofloxacin Hcl/Dexameth40$4,729
Ipratropium Bromide94$2,640
Ofloxacin46$1,087
Fluticasone Propionate68$617
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen11$566
Triamcinolone Acetonide27$564
Omeprazole40$469
Esomeprazole Magnesium17$445
Pantoprazole Sodium25$223
Pregabalin12$215
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen31$214
Mupirocin22$210
Prednisone32$195
Baclofen15$155

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Optinose US, Inc.Xhance$14$9,78215 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 210 otolaryngology providers in Missouri.

Other otolaryngology in Sikeston

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →